ADTX - Aditxtto acquire point-of-care diagnostic technology development company

Aditxt (NASDAQ:ADTX) to acquire a company focused on developing Point-of-Care diagnostics for early detection of diseases including cancers and SARS-CoV-2 through a range of non-invasive and affordable point of care and at-home/in-office test kits. The target holds an exclusive license in U.S. & Canada for at-home and in-office rapid antigen COVID-19 test. EUA application for the COVID-19 rapid antigen test was submitted in September 2021. “The potential acquisition is complementary to AditxtScore technologically and commercially, and is one of the main components to executing our growth plans in 2022. We believe that Point-of-Care rapid testing combined with our current capabilities is key to driving the transformation from reactive care to precision-driven, proactive care delivery.” said Amro Albanna, Co-Founder and CEO.

For further details see:

Aditxt,to acquire point-of-care diagnostic technology development company